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In brief
The SARS-CoV-2 Delta variant displaced
the previously dominant Alpha variant by
mid-2021, ostensibly because of 40%–
80% increased transmissibility. To
determine whether this difference is
uniform across populations, Earnest et al.
estimate variant-specific logistic growth
rates and effective reproductive numbers
for six states in New England finding
substantial heterogeneity.
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SUMMARY

The SARS-CoV-2 Delta variant rose to dominance in mid-2021, likely propelled by an estimated 40%–80%
increased transmissibility over Alpha. To investigate if this ostensible difference in transmissibility is uniform
across populations, we partner with public health programs from all six states in New England in the United
States. We compare logistic growth rates during each variant’s respective emergence period, finding that
Delta emerged 1.37–2.63 times faster than Alpha (range across states). We compute variant-specific effective
reproductive numbers, estimating that Delta is 63%–167% more transmissible than Alpha (range across
states). Finally, we estimate that Delta infections generate on average 6.2 (95% CI 3.1–10.9) times more viral
RNA copies per milliliter than Alpha infections during their respective emergence. Overall, our evidence suggests that Delta’s enhanced transmissibility can be attributed to its innate ability to increase infectiousness,
but its epidemiological dynamics may vary depending on underlying population attributes and sequencing
data availability.

INTRODUCTION
The evolution and emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants associated with
increased transmissibility, more severe disease, and/or decreased
vaccine effectiveness continue to exacerbate the coronavirus

disease 2019 (COVID-19) pandemic.1 A SARS-CoV-2 variant is a
virus with a defining set of mutations that distinguishes it from
viruses belonging to other lineages.2 In particular, two SARSCoV-2 variants with enhanced transmissibility substantially altered
the pandemic’s trajectory: Alpha (B.1.1.7 lineage) and Delta
(B.1.617.2 and AY.x sub-lineages). Alpha, defined in part by a
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N501Y amino acid substitution in the spike gene receptor binding
domain that may affect ACE2 binding, was first detected in the
United Kingdom in late 2020 and became the dominant global
variant by early 2021.3–5 Delta, containing the spike L452R and
P681H mutations (in the receptor binding domain and near the furin
cleavage site, respectively) that may affect antibody recognition,
was first recognized in India in early 2021 and displaced Alpha
as the dominant variant by mid-2021.5 This shift led to a significant
resurgence in COVID-19 cases in many countries.6–9
Transmission rates can be affected by two main factors: innate
attributes of the variant itself and the specific population in which
it spreads. Variant-associated attributes may lead to innately
increased transmissibility (e.g., increased viral loads, longer
infection duration, decreased infectious doses).10 The rapid
spread of Delta in many locations around the world suggests
that it is innately more transmissible than Alpha and other
SARS-CoV-2 variants. However, estimates of Delta’s transmissibility may also vary among populations because of differences
in underlying immunity, control measures, behaviors, and
demographics. For example, a variant that is more likely to cause
vaccine breakthroughs may have a larger observed transmissibility advantage in populations with higher vaccination rates
because it can spread to more individuals. In addition, the quality
and volume of data generated by sequencing programs in
different locations can influence estimates. Studies conducted
in the United Kingdom estimated that Delta is 40%–80% more
transmissible than Alpha, which itself was more transmissible
than the SARS-CoV-2 lineages previously in circulation.11 The
World Health Organization similarly estimated a 55% increase
in Delta transmissibility on the basis of data from India and the
United Kingdom.12 To understand whether these estimates are
applicable elsewhere, it is critical to compare the relative
transmissibility of SARS-CoV-2 variants in different locations to
test the sensitivity of estimates to population-specific
conditions. Accurate variant transmissibility estimates enable
us to begin exploring drivers of transmissibility differences
between populations.
In this study, we posed several important questions that arose
with Delta: (1) how much more transmissible was Delta
than Alpha, (2) what was the range in relative transmissibility
estimates across states, and (3) was Delta more transmissible
because it caused higher viral loads during infection? To
investigate each, we partnered with SARS-CoV-2 genomic
surveillance programs from all six New England states:
Connecticut, Maine, Massachusetts, New Hampshire, Rhode
Island, and Vermont. Using logistic growth rates and estimated
effective reproductive numbers,4,13,14 we found that Delta
was consistently more transmissible than Alpha, but the relative
difference varied across states. Furthermore, we found on
average 6.2 (95% confidence interval [CI] 3.1–10.9) times more
viral RNA copies per milliliter from samples collected from Delta
infections compared with Alpha infections during their respective emergence periods, supporting the hypothesis that Delta
may be more transmissible because it generates higher viral
loads. Overall, we estimated that Delta is 63%–167% more
transmissible than Alpha (range across states). Our data indicated that the overall transmission advantage of Delta may in
part be attributed to its innate ability to enhance infections and
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that the range in estimates between populations may be driven
by differences in underlying characteristics and sequencing
data availability.
RESULTS
Genomic surveillance revealed similar variant
frequency trajectories across New England
In response to emerging SARS-CoV-2 variants, all states within
the New England region of the United States (Connecticut,
Maine, Massachusetts, New Hampshire, Rhode Island, and
Vermont) increased their virus sequencing capacity through
local and regional partnerships (Figure 1A). From early April to
mid-July 2021, at least 5% of the weekly reported COVID-19
cases were being sequenced from each state (with the exception
of 7 days in June for New Hampshire and 10 days for Vermont
when daily mean coverage dropped to 4% and 2%, respectively). The maximum daily sequencing coverage ranged from
16% (New Hampshire) to 46% (Maine). From these state-level
sequencing data, we tracked the frequencies of the SARSCoV-2 Alpha variant (B.1.1.7 lineage), the Delta variant
(B.1.617.2 and AY.x sub-lineages), and all other lineages
(Figure 1B). We observed similar trajectories in variant frequencies, with other lineages declining as Alpha increased in
March and April 2021. Beginning in June 2021, Delta rapidly
displaced the Alpha and other lineages. We also observed that
the emergence of Delta resulted in a ‘‘selective sweep’’ and
more fully dominated the variant landscape compared with
Alpha. By the final week in July 2021, Delta constituted the
vast majority of sequenced samples in all states (range
94%–100%). In contrast, although Alpha was the main variant
in early 2021, we still observed other lineages maintained in
the population.
Delta emerged faster than Alpha and dominated the
variant landscape
Although Delta rose to dominance within several months of its
emergence (Figure 1), it was unknown how quickly it emerged
relative to Alpha in different populations. We addressed this
knowledge gap by comparing the initial growth rates of Delta
and Alpha across New England. As Alpha and Delta emerged
at different times, we defined their emergence periods as the
90 days following their initial detection in each state (Figure 2A).
We then estimated the logistic growth rate of Alpha and Delta
during their respective state-specific emergence periods
(Figure 2B). We found that Delta emerged faster than Alpha
despite higher vaccination rates during mid-2021.
Although Alpha appeared to initially outpace Delta, as
indicated by its steeper growth curve during the early emergence
period (Figure 2B), we hypothesized that this was due to gaps in
surveillance programs that impeded detection of Alpha but were
addressed before Delta emerged. In some states, the predicted
probability of a given sequence belonging to Alpha is non-zero at
the time of first phylogenetic detection, providing further support
for this hypothesis. As noted previously (Figure 1A), sequencing
coverage improved over time in all states as incident cases
declined. The probability of a given sequenced sample
belonging to Alpha at the start of its emergence period was
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Figure 1. SARS-CoV-2 sequencing coverage and variant frequency tracking
(A) Confirmed cases per 100,000 population (bars) and percentage of cases sequenced (lines) by state (7 day rolling average), January to August 2021. The
variability in percentage of cases sequenced represents changing sample availability and suitability for sequencing. The drop in percentage sequenced at the end
of August does not reflect real decreases in sequencing coverage but instead (1) the 1 to 3 week delays between sample collection and sequence availability and
(2) how the data are plotted using 7 day rolling averages.
(B) Weekly proportion of sequenced genomes belonging to each variant category with 95% confidence intervals, January to August 2021. A breakdown of the
number of genomes (n = 33,408) by state and lineage is included in Tables S1–S3.

11% in Vermont, 8% in Connecticut, and between 1% and 2% in
the remaining states, indicating that Alpha likely was circulating
for some time before its first detection (Figure 2B). In contrast,
the probability of a given sequenced sample belonging to Delta
was 0% at the start of the emergence period in all states. We
estimated that the logistic growth rate for Delta was 2.63 times
greater than Alpha in Vermont, 2.51 times greater in Connecticut,
1.98 times greater in Rhode Island, 1.95 times greater in Maine,
1.75 times greater in New Hampshire, and 1.37 times greater in
Massachusetts (Figure 2C). From the first sequenced detection,
it took Delta on average 71 days (range across states

54–92 days) to become dominant (to surpass 50% predicted
frequency; Figure 2B). Given that the Alpha and Delta variants
circulating across New England were intermixed, the differences
in the growth rates between states are likely due in part
to population-specific factors. As an initial exploration, we
compared the increase in the logistic growth rate for Delta versus
Alpha with the vaccination rates or estimated infections (Figure 2A) per state at the start of the Delta emergence period.
We noted an association between the relative emergence speed
of Delta with state vaccination rates; however, states with earlier
Delta detection dates, such as Massachusetts, necessarily have
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Figure 2. Variant logistic growth rates during their respective emergence periods in the context of infections and vaccination
(A) Estimated infections per 100,000 population (gray bars, left axis) and percentage of the population fully vaccinated (black lines, right axis) (7 day rolling
average), with the colored rectangles indicating the 90 day emergence periods for each variant.
(B) Predicted probability of a given sequence belonging to each variant category over time determined by a binomial logistic regression for the variant category as
the outcome and the number of days since the first detection as the predictor, estimating the logistic growth rate for Alpha versus Delta. Shown with 95%
confidence intervals. The analysis is restricted to the first 90 days of emergence in each state as shown in (A). During the Alpha emergence period, we had the
following number of Alpha genomes for each state: Connecticut, n = 1;221; Maine, n = 508; Massachusetts, n = 2;062; New Hampshire, n = 298; Rhode Island, n =
641; and Vermont, n = 466. During the Delta emergence period, we had the following number of Delta genomes for each state: Connecticut, n = 301; Maine, n =
108; Massachusetts, n = 268; New Hampshire, n = 30; Rhode Island, n = 136; and Vermont, n = 82.
(C) The regression coefficients (slopes) of the logistic growth rate from (B) with 95% confidence intervals. A sensitivity analysis varying the emergence periods
by ±30 days is presented in Figure S1 and Table S4.

lower vaccination rates during the Delta emergence period. We
did not note an association between the relative emergence
speed of Delta and estimated infections per 100,000 population
in each state. Finally, we performed a sensitivity analysis varying
the emergence period by ±30 days from the selected 90 day
emergence period (Figure S1; Table S4). Using a 60 day
emergence period, Delta emerged 1.30–1.57 times faster (range
across states) in all states except Maine and New Hampshire,
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where Alpha emerged 2.33 and 4.55 times faster than Delta,
respectively. Using a 120 day emergence period, Delta emerged
1.97–3.30 times faster (range across states).
Delta was more transmissible than Alpha in all New
England states
We showed that Delta emerged faster in New England than
Alpha had previously (Figure 2) and rose to higher levels of
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Figure 3. Comparison of variant effective reproductive numbers to estimate relative transmissibility
(A) Estimated effective reproductive number (Rt) over time for each variant category calculated from the inferred number of infections using EpiEstim.15,16 We
used a multi-step bootstrap sampling approach to generate 1,000 samples containing the estimated number of variant-specific infections. We obtained mean Rt
estimates for each of the 1,000 bootstrapped samples and plotted the overall mean and 95% confidence intervals (2.5% and 97.5% quantiles across the
bootstrapped samples). Note that the y axis differs from that in (B).
(B) Daily mean ratios of Rt values for Delta compared with Alpha from (A). For each bootstrapped sample described in (A), we calculated the daily ratio of the Delta
to Alpha Rt estimates. We plotted the mean across the 1,000 bootstrapped samples and the 95% confidence intervals, calculated the same as in (A). For (A) and
(B), the upper limit of Delta’s confidence intervals in Maine, New Hampshire, and Vermont are not plotted but are displayed in Figures S2B and S2C.

dominance, almost completely displacing Alpha and other
lineages (Figure 1). However, we still do not know how much
more transmissible Delta was than Alpha when they were cocirculating and the extent to which our estimates varied across.
To answer this question, we adapted our previously developed
framework to estimate the variant-specific effective reproductive
number (Rt) from inferred SARS-CoV-2 infections.13,15 Our Rt
estimates for each variant approximate the time-varying average
number of secondary cases from a primary infection within a
population. Rt estimates greater than 1 imply that COVID-19

cases associated with variants will increase in the future. We
report the length of the Alpha/Delta co-circulation period
(STAR Methods) and estimated mean Alpha and Delta infections
per 100,000 population during the co-circulation period for each
state (Figure S2A). We computed Rt for each variant category
during January to August 2021 (Figure 3A) by combining the
frequency estimates from our genomic surveillance data (Figure 1B) with daily estimated SARS-CoV-2 infections (Figure 2A).
Specifically, we used a multi-step bootstrapped sampling
approach to generate 1,000 samples containing the estimated
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number of variant-specific infections. Our approach is further
detailed in STAR Methods. Delta had Rt > 1 for the majority of
the time period following its emergence, which exceeded the
Rt estimates for Alpha and other lineages (Figure 3). Our mean
Rt estimates for other lineages was <1 for all states, ranging
from 0.87 to 0.91. Prior to the emergence of Delta, our mean Rt
for Alpha was 1.20 across states, dropping to a mean of 0.78
as vaccination increased during the period following Delta’s
emergence. Our mean Rt estimate for Delta was 1.40, ranging
from 1.27 (New Hampshire) to 1.65 (Vermont). We found that
the Rt for Delta exceeded that of Alpha in all states for the
majority of the time following its initial detection (Figure 3B).
We then estimated that the mean Rt ratio of Delta to Alpha
during their co-circulation period was 2.67 in Vermont, 2.04 in
Maine, 1.92 in New Hampshire, 1.83 in Rhode Island, 1.78 in
Connecticut, and 1.63 in Massachusetts, suggesting that Delta
was 63%–167% more transmissible on average than Alpha
(range across states).
In addition, separately for Delta and Alpha, we calculated the
multiplicative increase in Rt, another measure of relative transmissibility (Figure S3).14 For this estimate, we exponentiated
the coefficients from the binomial logistic regression and multiplied them by the mean generation interval to estimate the
change in the probability of a given sequence belonging to a lineage over a generation interval. The multiplicative increase in Rt
for Delta was greater than that for Alpha in all states. Across
states, we observed a mean 1.30 increase in the probability of
a sample belonging to Alpha over a generation interval,
compared with 1.69 for Delta. Our multiplicative increase in Rt
estimates suggests that Delta had the greatest advantage in
Maine (1.99-fold increase) and the lowest advantage in Massachusetts (1.45-fold) (Figure 3C). Differences in transmissibility
estimates between states may be due to a combination of viral,
underlying population, and data factors that are further
described in the Discussion.
Delta infections on average had a larger number of viral
RNA copies than Alpha infections during their
respective emergence periods
One potential mechanism for Delta’s increased transmissibility
relative to Alpha (Figures 2 and 3) is that infections with the Delta
variant could lead to higher virus titers than those with Alpha. To
test this hypothesis, we compared the qRT-PCR cycle threshold
(CT) values of sequence-confirmed Alpha and Delta infections
(anterior nares or nasopharyngeal swabs) available from four
institutes in New England: Yale University (Connecticut), Jackson Laboratory (Connecticut), Mass General Brigham (Massachusetts), and the Health and Environmental Testing Laboratory
(Maine) (Figure 4). PCR CT values are a metric of virus RNA
copies, and lower CT values indicate that there are more copies.
We consistently found lower CT values for Delta infections
across all institutes, but some comparisons did not yield significant differences.
Importantly, PCR CT values from cross-sectional tests can be
biased by the epidemic period because viral loads are dynamic
and tend to decrease with time.18 During the emergence phase
of an epidemic, most PCR tests come from recent infections,
whereas the opposite is true when the epidemic is declining.
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The result is that PCR CT values could be higher (meaning less
virus detected) during the declining phase even though the
infection dynamics are the same throughout the epidemic. We
first investigated if variant-specific PCR CT values change during
different epidemic phases by running a one-way ANOVA for
Alpha and Delta samples (separately) generated by one of the
institutes (Yale University) to test for significant differences
between monthly mean CT values (Figures S4A and S4B). We
found a significant difference for only the Alpha samples. Using
a post hoc Tukey’s honestly significant difference (HSD) test to
investigate pairwise differences in monthly CT values while
controlling for the experiment-wise error rate, we found that for
the Alpha samples, there was a significant difference only for
March versus April. If the epidemic phase were affecting our
mean monthly CT values, we would expect higher CT values
(corresponding to lower viral loads) for April versus March, as
April is further in the declining phase of Alpha. We observe the
opposite, providing further support for our previous finding that
we did not observe evidence of an epidemic phase effect on
our monthly CT values. Still, to account for any effects that the
epidemic period may have on our comparisons, we limited our
analysis to the approximate emergence phase of each variant:
January to March 2021 for Alpha and June to August for Delta.
Furthermore, the PCR CT data that we used from the four
institutes are from different assays and some target different
genes (though most target the nucleocapsid [N] gene). The
Yale University data are from the N1 primer/probe set (originally
from the ‘‘Centers for Disease Control and Prevention [CDC]
assay’’) of a ‘‘research use only’’ assay17; the Health and
Environmental Testing Laboratory data are from the same N1
primer/probe set at Yale but from the OPTI SARS-CoV-2 RTPCR Test; the Jackson Laboratory data are from the N gene
primer/probe set of the TaqPath COVID-19 Combo Kit; and the
Mass General Brigham data are from the envelope (E) and
open reading frame 1a (ORF1a) gene primer/probe set of the
Roche Cobas SARS-CoV-2 test. Therefore, we analyzed the
PCR CT values independently for each institute and gene target.
Assessing cross-sectional PCR data from the four institutes,
we consistently found lower mean CT values (more viral RNA
copies) from Delta compared with Alpha nasal swab samples
(Figure 4). The differences were significant from the Yale
University (p % 0.0001) and Jackson Laboratory (p % 0.001)
data, but not from Mass General Brigham and the Health and
Environmental Testing Laboratory (p > 0.05 for each). In addition,
for the Yale University samples, we used a standardized PCR
curve to translate the CT values into viral RNA copies per
milliliter.19 We found 6.2 (95% CI 3.1–10.9) times more RNA
copies per milliliter (non-log scale) on average in Delta anterior
nares swab samples compared with Alpha samples (Figure S4C).
Thus, during their respective emergence periods, upper respiratory tract samples collected from individuals infected with Delta
on average had higher viral copies than from Alpha infections,
possibly contributing to enhanced transmissibility. An important
limitation of this analysis is that viral load differences may change
later in each variant’s epidemic trajectory as PCR tests increasingly come from less recent infections, and thus our findings are
restricted to the respective emergence periods. We discuss our
CT analysis limitations further in the Discussion.
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Figure 4. Cross-sectional PCR data from Alpha and Delta samples
PCR CT values (inverted y axis) plotted by institute and variant category, limiting Alpha samples to January to March 2021 and Delta samples to June to August
2021 to account for their respective emergence periods. Monthly CT values for Alpha and Delta for Yale University are shown in Figures S4A and S4B. For each
institute, the means of the two variant categories were compared using a t test, with statistical significance symbols corresponding to the following values: ns
(p > 0.05), ***p % 0.001, and ****p % 0.0001. Data from the full month of August were not available for most of the institutes at the time of analysis. The Yale
University (Connecticut) Alpha (n = 541) and Delta (n = 250) data are from the N1 primer/probe set (originally from the ‘‘CDC assay’’) of a research use-only
RT-PCR assay to discriminate among variants (data shown as virus RNA copies per milliliter in Figure S4C).17 The Jackson Laboratory (Connecticut) Alpha
(n = 204) and Delta (n = 60) data are from the N gene primer/probe set of the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific). The Mass General Brigham
(Massachusetts) Alpha (n = 41) and Delta (n = 153) data are from the E gene of the Roche Cobas SARS-CoV-2 test (ORF1a data shown in Figure S4D). The Health
and Environmental Testing Laboratory (Maine) Alpha (n = 16) and Delta (n = 88) data are from the N1 primer/probe set (originally from the ‘‘CDC assay’’) of the OPTI
SARS-CoV-2 RT-PCR Test (OPTI Medical Systems).

DISCUSSION
The SARS-CoV-2 variant Delta emerged across the United
States in mid-2021, displacing previous variants, including
Alpha. Assessing the variability in relative emergence growth
rates and transmissibility estimates of Delta versus Alpha across
different settings remains an important public health question.
With more than 3 million SARS-CoV-2 genomes available in
public repositories, large-scale and globally diverse assessments can be conducted. However, there is always a risk
when analyzing diverse sources of data without input from the
data submitters on possible sampling biases (e.g., targeted
sequencing in certain settings or sub-state locations) that may
not be apparent in the repositories. We directly partnered with
SARS-CoV-2 genomic surveillance programs from all six states
in the New England region of the United States (Figure 1) to
confidently assess emergence growth rates and relative
transmissibility at the state level. We found that the logistic
growth rates (Figure 2) and effective reproductive numbers

(Figure 3) of Delta were consistently greater than Alpha across
all New England states, although there was variation among
states.
The estimated initial growth rates for Alpha and Delta
could have been influenced by population factors that differed
between each variant’s respective emergence period. At the
time of Alpha’s emergence in January and February 2021, 0%
of the population across New England was reported as being
fully vaccinated (Figure 2A). In comparison, when Delta first
emerged in March and April 2021, 18%–37% of the population
was fully vaccinated. Estimated infections per 100,000
population were also substantially lower during Delta’s emergence period (Figure 2A). However, with rising vaccination rates,
all of the states began relaxing capacity constraints from late
February to late March 2021. States continued rolling back
COVID-19 mitigation measures with the majority lifted by the
end of May 2021, although some states maintained indoor masking for unvaccinated individuals.20 The emergence of Delta also
occurred within the background of other variants, including
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Alpha (Figure 1B). Thus, the fitness landscape for SARS-CoV-2
variants may have changed dramatically during 2021, potentially
playing out differently across the states and explaining the large
range in relative growth rates between Delta and Alpha
(Figure 2C). Finally, the initial growth rates are sensitive to the
length of the emergence period (Figure S1). We found
consistently faster relative growth rates for Delta versus Alpha
when using a longer emergence period (120 days instead of
90 days) but had mixed findings when using a shorter emergence
period (60 days instead of 90 days) (Table S4). Shorter emergence periods may exacerbate the potential aforementioned
biases in surveillance between Alpha and Delta, leading to
more variable results. This underscores the importance of
understanding the sequencing context in the early days of a
variant’s emergence when making these estimates.
Our estimates of the transmission advantage (measured as the
mean Rt ratio of Delta to Alpha) for Massachusetts (63%) and
Connecticut (78%) were within the 40%–80% estimate range
provided by the United Kingdom.11 We estimated a greater
transmission advantage for Delta in Rhode Island (83%), New
Hampshire (92%), Maine (104%), and Vermont (167%). This
variation may be driven by differences in the underlying state
populations, such as population density, vaccination rates,
travel patterns, control measures, behaviors, and competing
variants in circulation. In addition, the differences could reflect
the noisier Delta Rt estimates we observed for states with fewer
infections and, as a result, fewer genomic sequences. In
particular, we noted wide confidence intervals around the Delta
Rt estimates for Maine, New Hampshire, and Vermont, the states
with the greatest Delta to Alpha transmission advantage
(Figures S2B and S2C). It is possible that additional sequencing
data from these states would bring their estimates of relative
transmissibility more in line with those from other locations.
Our study adds to the growing evidence that Delta may be
more transmissible in part by causing higher viral loads during
acute infections.21–25 We found significantly lower mean PCR
CT values (corresponding to more viral RNA copies) for Delta
versus Alpha infections from nasal swab samples tested by
Yale University and Jackson Laboratory in Connecticut (Figure 4).
The overall pattern of lower CT values for Delta versus Alpha held
for the Massachusetts and Maine data, although the differences
in mean values were not significant. This may be due to relatively
small sample sizes for Alpha in those locations, specimen type
used for analysis (anterior nares vs. nasopharyngeal swab),
and/or changing CT cutoff criteria for sequencing (e.g., the Alpha
CT values from Mass General Brigham do not extend above 31,
suggesting a stringent cutoff). For the Yale data, we used a
standardized curve to translate the CT values into virus copies
and found that Delta samples had on average 6.2 (95% CI
3.1–10.9) times more viral RNA copies per milliliter than
Alpha samples during their respective emergence periods
(Figure S4C).
In conclusion, although we determined that the Delta SARSCoV-2 variant emerged faster and was more transmissible than
Alpha in New England, there was heterogeneity in our estimates
across states. Our analysis demonstrated that, in addition to
possible innate differences between variants, there may be other
factors at play such as vaccination levels, transmission levels,
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demographics, behavior, control measures, and sequencing
data availability that affected each variant’s estimated
transmissibility within a given population. Finally, state
sequencing volumes and coverage variability may be partly
behind the range of estimates that we observed. The exact
mechanisms driving differences in variant transmissibility among
states are unclear, but these factors remain important when
considering how another variant might rise to dominance in the
future and the sequencing data required to accurately assess
its ascent. It is impossible to predict when and where the next
variant of concern will emerge, as the explosive recent
emergence of Omicron has shown, and thus it is important to
enhance SARS-CoV-2 genomic surveillance and further our
understanding of how different population characteristics and
sequencing data availability affect variant transmissibility
estimates.
Limitations of the study
An important limitation to our comparative analyses was that
sequencing coverage improved in states over time (Figure 1A),
and thus there may have been a greater delay in the time
to the first sequenced detection for Alpha versus Delta. In addition, because of the uncertainty around the serial interval, we
selected an uncertain serial interval approach to explore various
possible distributions when calculating Rt (STAR Methods). Our
state-specific results should be considered within the context of
their variability in sequencing coverage and the volume of sequences. Overall, the states with the greatest Delta to Alpha
transmission advantage (Vermont, Maine, and New Hampshire)
also had the widest confidence intervals around their Rt estimates (Figures S2B and S2C), reflecting the challenges of estimating variant-specific Rt values when relatively few genomic
sequences are available. In particular, Vermont had more
variable sequencing coverage because of low case counts,
and its results should be interpreted cautiously (Figure 1A).
Thus, variant frequencies based on a relatively small number of
sequences are likely driving some of the uncertainty around Rt
estimates and variability across states (Figures 3A, S2B, and
S2C). In addition, we did not account for the lag between the
time of estimated infections and when the sequenced samples
were collected, but we do not believe that this would have a
substantial impact on our Rt estimates, particularly given the
21 day sliding window we used. We conducted our analysis at
the state level, however there could be within-state heterogeneity in our estimates. Drivers of heterogeneity could include a lack
of even sequencing coverage across each state. We attempted
to assess the within-state location of each sequence used in our
analysis, but only the state location was typically available
among publicly available data. In addition, there could be
differences in population demographics, behavior, immunity,
and/or control measures at more local levels that could lead to
more heterogeneous estimates.
For the PCR CT analysis, we necessarily used only confirmed
variant sequence data, which represents a fraction of the total
PCR CT data and is biased against higher CT values that lack
sufficient virus RNA for sequencing. It is also important to be
cautious in interpreting CT values among institutes because of
differences in the diagnostic PCR test platforms, specimen types

Please cite this article in press as: Earnest et al., Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA, Cell
Reports Medicine (2022), https://doi.org/10.1016/j.xcrm.2022.100583

ll
OPEN ACCESS

Article
included, and subsequent CT cut-off values. For this reason, we
did not aim to directly compare institutes but rather sought to
establish whether an overall pattern of lower CT values for Delta
versus Alpha samples held. Mean CT values can also be
influenced by the epidemic trajectory, as discussed previously.
To assess whether we observe this in our data, we plotted Alpha
and Delta CT values (separately) by month for the Yale data
(Figures S4A and S4B) and did not find a pattern in monthly
mean CT values indicative of a bias due to the epidemic
trajectory. To further control for possible differences in CT
values driven by the epidemic trajectory, we also limited our
comparison of mean viral loads between variants to only the
initial 3 months following their respective emergence. Additional
patient metadata such as estimated time since infection would
enable a more extensive analysis in differences in variant viral
loads.
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STAR+METHODS
KEY RESOURCES TABLE

REAGENT or RESOURCE

SOURCE

IDENTIFIER

SARS-CoV-2 genomes

GISAID

https://www.gisaid.org/

Confirmed COVID-19 cases

Johns Hopkins Center for Systems
Science and Engineering

https://github.com/CSSEGISandData/COVID-19

Estimated COVID-19 infections

Covidestim

https://covidestim.org/

2019 U.S. state populations

United States Census Bureau

https://www.census.gov/

State population vaccination percentages

Centers for Disease Control and
Prevention

https://data.cdc.gov/

R

RStudio: Integrated
Development for R

Version 1.4.1106

EpiEstim: Estimate Time Varying Reproduction
Numbers from Epidemic Curves (R Package)

Cori et al., 2013

Version 2.2-4

Connecticut SARS-CoV-2 PCR CT values

Yale University, Jackson Laboratory

https://github.com/grubaughlab/2021_paper_
Delta-v-Alpha

Massachusetts SARS-CoV-2 PCR
CT values

Mass General Brigham

https://github.com/grubaughlab/2021_paper_
Delta-v-Alpha

Maine SARS-CoV-2 PCR CT values

Health and Environmental
Testing Laboratory

https://github.com/grubaughlab/2021_paper_
Delta-v-Alpha

Deposited data

Software and algorithms

Other

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and data should be directed to and will be fulfilled by the lead contact, Dr. Nathan
Grubaugh (nathan.grubaugh@yale.edu).
Materials availability
This study did not generate any unique reagents, but raw data and code for this study can be found in the Supplemental Materials and
via the resources specified in Data and Code Availability.
Data and code availability
A summary of the SARS-CoV-2 lineages used from GISAID are available in Tables S1–S3. A complete list of GISAID acknowledgements and all original code and data have been deposited at Github and are publicly available as of the date of publication (https://
github.com/grubaughlab/2021_paper_Delta-v-Alpha). Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethics statement
Yale University (Connecticut)
The Institutional Review Board from the Yale University Human Research Protection Program determined that the RT-qPCR testing
and sequencing of de-identified remnant COVID-19 clinical samples obtained from clinical partners conducted in this study is not
research involving human subjects (IRB Protocol ID: 2000028599).
Jackson Laboratory (Connecticut)
The Institutional Review Board of The Jackson Laboratory determined that use of de-identified residual COVID-19 clinical samples
obtained from the Clinical Genomics Laboratory for RT-qPCR testing and sequencing for this study is not research involving human
subjects (IRB Determination: 2020-NHSR-021).
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Mass General Brigham (Massachusetts)
The Institutional Review Board of Partners Human Research determined that the use of excess, de-identified COVID-19 clinical
specimens obtained within the Partners Healthcare network for RT-qPCR testing and genomic sequencing for this study is not
research involving human subjects (IRB Protocol ID: 2019P003305). In addition, the Institutional Review Board of the Massachusetts
Department of Public Health has reviewed and approved this study to perform genomic sequencing of coronaviruses (IRB Protocol
ID: 1603078).
Health and Environmental Testing Laboratory (Maine)
A Memorandum of Understanding between The State of Maine Department of Health and Human Services and The Jackson
Laboratory determined that extracted viral RNA from human respiratory specimens which have tested positive for SARS-CoV-2
and are used for sequencing will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects.
METHOD DETAILS
Growth rates and transmissibility estimation
Genomic surveillance data
We obtained SARS-CoV-2 genomic sequence data from GISAID as of August 13, 2021.26–28 We restricted the dataset to our states of
interest (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont) and removed sequences that lacked a
lineage assignment (N = 4977), had mismatched metadata for the sample collection location (N = 81), or were outside of our January
1, 2021 - August 1, 2021 time period of interest (N = 4260). This yielded a final dataset of 33,408 genomes. We categorized the GISAID
SARS-CoV-2 genomes into 3 mutually exclusive categories: Alpha (B.1.1.7), Delta (B.1.617.2 and all AY.x sub-lineages existing as of
August 13, 2021), and Other (any sequences not included in the prior categories that had a lineage assignment). A breakdown of the
number of genomes by state and lineage is included in Tables S1–S3.
Confirmed cases per 100K population
We obtained confirmed case data from the Johns Hopkins Center for Systems Science and Engineering.29 We used state population
estimates for 2019 from the United States Census Bureau to calculate confirmed cases per 100K population (Figure 1A).30
Percent of the population fully vaccinated
We obtained the percent of the state populations that were fully vaccinated from the Centers for Disease Control and Prevention
(dataset downloaded August 11, 2021) (Figure 2A).31
Infections per 100K population
We obtained estimated infections for each state from Covidestim, a Bayesian nowcasting approach that accounts for differences in
diagnosis and reporting by anchoring its estimates to death data, which are generally more reliable than case data (dataset
downloaded November 11, 2021).15 We used state population estimates for 2019 from the United States Census Bureau to calculate
estimated infections per 100K population (Figure 2A).30
RT-qPCR and lineage identification
Yale University (Connecticut)
Clinical samples (anterior nares in viral transport media) were received from confirmed SARS-CoV-2 positive individuals from routine
testing provided by Yale New Haven Hospital. The samples were primarily from Connecticut and were collected for a variety of
inpatient and outpatient testing programs. Nucleic acid was extracted from 300 mL of the original sample using the MagMAX viral/
pathogen nucleic acid isolation kit, eluting in 75 ml of elution buffer. The extracted nucleic acid was tested for SARS-CoV-2 RNA using
a ‘‘research use only’’ (RUO) RT-qPCR assay.17 For this analysis, only the CT values from the CDC N1 primer/probe set were used
(Figure 4). N1 CT values were also converted into SARS-CoV-2 RNA copies using a standard curve, as previously described
(Figure S4C).19
To determine the SARS-CoV-2 lineage, samples with CT values % 35 were sequenced using the Illumina COVIDSeq Test RUO
version. Amplicons were pooled and cleaned before quantification with Qubit High Sensitivity dsDNA kit. The resulting libraries
were sequenced using a 2x150 approach on an Illumina NovaSeq at the Yale Center for Genomic Analysis. Each sample was given
at least 1 million reads. Samples were typically processed in sets of 93 or 94 with negative controls incorporated during the RNA
extraction, cDNA synthesis, and amplicon generation steps. The reads were aligned to the Wuhan-Hu-1 reference genomes
(GenBank MN908937.3) using BWA-MEM v.0.7.15.32 Adaptor sequences were trimmed, primer sequences were masked, and
consensus genomes were called (simple majority >60% frequency) using iVar v1.3.133 and SAMtools.34 An ambiguous ‘N’ was
used when fewer than 20 reads were present at a site. In all cases, negative controls were analyzed and confirmed to consist of
at least 99% Ns. Pangolin v.2.4.235 was used to assign lineages.36
Jackson Laboratory (Connecticut)
Clinical samples were received in The Jackson Laboratory Clinical Genomics Laboratory (CGL) as part of a statewide (Connecticut)
COVID-19 surveillance program, with the majority of samples representing asymptomatic screening of nursing home and assisted
living facility residents and staff. Total nucleic acids were extracted from anterior nares swabs in viral transport media or saline
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(200 mL) using the MagMAX Viral RNA Isolation kit (ThermoFisher) on a KingFisher Flex purification system. Samples were tested for
the presence of SARS-CoV-2 RNA using the TaqPath COVID-19 Combo Kit (ThermoFisher). For this analysis, only the CT values from
the N gene primer/probe set were used (Figure 4).
Samples with CT values % 30 for the N gene target were prepared for sequencing using the Illumina COVIDSeq Test kit.
Sequencing was performed on an Illumina NovaSeq or NextSeq in the CGL. Data analysis was performed using the DRAGEN COVID
Lineage App in BaseSpace Sequence Hub. Sequences with >80% of bases with non-N basecalls and R1500-fold median coverage
were considered successful and were submitted to GISAID. Lineages were assigned using pangolin v.2.4.235 and the most current
version of the pangoLEARN assignment algorithm.
Mass General Brigham (Massachusetts)
Clinical samples were received from confirmed SARS-CoV-2 positive tests collected at Massachusetts General Brigham testing
facilities during routine testing, via nasopharyngeal swabs in viral or molecular transport media. Clinical samples included in the
analysis were tested for the presence of SARS-CoV-2 RNA using the Roche Cobas SARS-CoV-2test on the 6800 system, targeting
both the E and ORF1a genes. CT values were analyzed independently for both the E (Figure 4) and ORF1a (Figure S4D) gene primer/
probe sets.
Genomic sequencing was conducted on clinical samples with CT values %30 using the Illumina COVIDSeq Test protocol. The
resulting libraries were pooled, cleaned, and quantified using the Qubit High Sensitivity dsDNA kit. Sequencing was performed at
Massachusetts General Hospital or at the Broad Institute of MIT and Harvard using a 2x150 approach on an Illumina NovaSeq
SP, an Illumina NextSeq 550, or an Illumina NextSeq 2000. Sequences were analyzed through the Broad Institute Data Analysis Platform using the viral-ngs 2.1.28 on the Terra platform (app.terra.bio). All of the workflows named below are publicly available via the
Dockstore Tool Registry Service (dockstore.org/organizations/BroadInstitute/collections/pgs). Sequences with an assembly length
>24000 non-N bases were considered complete genomes. Lineages were assigned using the most up-to-date version of the
pangoLEARN assignment algorithm.
Health and Environmental Testing Laboratory (Maine)
Clinical samples (anterior nares swabs in viral transport media) were received from confirmed SARS-CoV-2 positive tests collected at
the State of Maine Department of Health and Human Services testing facilities (Health and Environmental Testing Laboratory (HETL))
during routine testing. Viral RNA were extracted on a Thermofisher KingFisher Flex purification using the MagMAX Viral/Pathogen II
Nucleic Acid Isolation Kit. Extracted samples were tested for the presence of SARS-CoV-2 RNA using the OPTI SARS-CoV-2
RT-PCR Test (OPTI Medical Systems) with the ABI 7500fast DX thermocycler. For this analysis, only the CT values from the N1
gene primer/probe set were used (Figure 4).
Prior to sequencing, samples were not reanalyzed for the presence of SARS-CoV-2 RNA. HETL utilized the QIAseq DIRECT SARSCoV-2 Kit from Qiagen for targeted whole genome library preparation. Samples were sequenced on an Illumina MiSeq using a
MiSeq" Reagent Kit v2 (300 cycle) kit. QIAGEN CLC Genomics Workbench was used to assemble viral genomes. Consensus
sequences were uploaded to Nexstrain and Pango for quality control, strain and clade identification.
Additional SARS-CoV-2 positive samples from HETL were sequenced by the Jackson Laboratory (Maine) using the Illumina
COVID-Seq protocol modified to include 6e2 copies/mL of a unique SDSI control spiked into each cDNA sample. Samples were
sequenced on a NextSeq500 using paired 75 bp reads by the Genome Technology group on Jackson Laboratory’s Bar Harbor
campus. Sequence reads were analyzed using an in-house pipeline (https://github.com/tewhey-lab/SARS-CoV-2-Consensus)
that leverages minimap2, samtools and iVar for read mapping and variant calling. Sequences with >80% non-N bases were
considered complete genomes for analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
We used RStudio (v 1.4.1106) for all analyses and figures.37 Statistical details are available in figure legends and in the below STAR
Methods section.
Growth rates and transmissibility estimation
Sequencing coverage
We calculated sequencing coverage per state as the number of curated sequenced genomes made publicly available on GISAID
divided by the number of confirmed cases, and plotted the data based on the sample collection date using a 7-day rolling average
(Figure 1A).
Variant frequencies among sequenced samples
We divided the number of sequences belonging to each variant category (Delta, Alpha, or Other) by the total number of sequences
with an assigned lineage to estimate variant frequencies. We calculated a Jeffreys’ interval, using the resulting 0.025 and 0.975
quantiles to form a 95% confidence interval (Figure 1B).
Logistic growth rates
We first defined the emergence period for Alpha versus Delta in each state as the time from each variant category’s first phylogenetic
detection in the GISAID data to 90 days afterward. We ran a binomial logistic regression for Alpha and Delta, separately, with the
variant category as the outcome and the number of days since the first detection as the predictor. We plotted the smoothed fitted
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curves for the emergence periods with their 95% confidence intervals (Figure 2B), which shows the probability of a given sequence
belonging to a specific variant category over time. We also reported the logistic regression coefficients as the log odds of a given
sequence belonging to a specific variant category (Figure 2C). Finally, we ran a sensitivity analysis varying the emergence
period +/! 30 days from our selected 90-day period (Figure S1 and Table S4). In Table S4, we report the ratio of the regression
coefficients (slopes) of the logistic growth rate shown in Figure S1 for Delta versus Alpha for each state and emergence period.
Effective reproductive number Rt estimates and Rt ratios
To reflect the uncertainty around whether our sampled variant frequencies were representative of the full unknown population of
infections, we took a multi-step bootstrapping approach. First, we drew the number of variant-specific genomes Yiv from a
multinomial distribution where the number of independent trials was equal to the total number of sequences on day i and the
probability of a sequence on day i belonging to variant v being equal to its frequency on day i. We then calculated the sample
probability Piv of variant v on day i. We repeat this sampling process 1,000 times.
Yi;v " MultðSi ; pÞ
Yi;v = number of sequences on day i belonging to variant v
Si = total number of observed sequences on day i
p = ðpi; alpha ; pi; delta ; pi; other Þ = probability of a sequence on day i belonging to variant v
pi;v =

Xi;v
= proportion of total sequences on day i belonging to variant v
Si

Pi;v =

Yi;v
= sample probability of variant v on day i
Si

Next, using our sampled variant proportions, we sampled again from a multinomial distribution 1,000 times. In this case, the
number of independent trials was equal to the number of estimated infections on day i and the probability of an infection on day i
belonging to variant v being equal to its sample probability Piv. The result for each sample was a time series of the estimated number
of Alpha, Delta, and Other infections. We applied a 7-day rolling average to these data to account for day-of-the-week differences in
sequence reporting.
Zi;v " MultðIi ; PÞ
Zi;v = number of estimated infections on day i belonging to variant v
Ii = total number of estimated infections on day i
P = ðPi; alpha ; Pi; delta ; Pi; other Þ = probability of an infection on day i belonging to variant v
Finally, following a previous approach used to estimate the comparative transmissibility of SARS-CoV-2 variants,13 we ran each
time series through the EpiEstim R package16 to obtain our mean Rt estimates. Within EpiEstim, we used an uncertain serial interval
to estimate Rt over 21-day sliding windows, with the mean serial interval of 5.2 days (allowed to vary between 2.2 and 8.2 days) and a
standard deviation of 4 days (allowed to vary between 2.5 and 5.5 days) based on estimates available in the literature.38–40 For
Vermont, we removed a single ‘Other’ variant category sequence on July 21, 2021 (after the ‘Other’ variant category had died
out) that was leading to highly inflated Rt estimates. We began Rt estimation when there were at least 12 cumulative estimated
infections to achieve a posterior coefficient of variation of 0.325 and restricted estimation to before August 1, 2021 as variant
frequencies became less certain after that time due to delays in sequencing and reporting. We further truncated the variant-specific
Rt estimates in states where estimated variant-specific infections went consistently to 0 (i.e. died out). EpiEstim assumes an
uninformative prior for mean Rt of 5, ensuring that when there are few infections (e.g., zero variant-specific infections for the majority
of the 21-day estimation window) the prior becomes disproportionately weighted relative to the data. As a result, in the case of a
lineage die-out, Rt estimates erroneously seem to increase. Therefore, we truncated the Rt estimates at the date where the lineage
died out. For Alpha Rt estimates, we truncated the following states: Connecticut (July 24, 2021), Maine (July 13, 2021), New
Hampshire (July 23, 2021), Rhode Island (July 17, 2021), and Vermont (July 11, 2021). For Other Rt estimates, we truncated the
following states: New Hampshire (July 20, 2021), Rhode Island (July 25, 2021), and Vermont (June 25, 2021). We did not truncate
any of the Delta Rt estimates as Delta infections grew in all states during our studied time period. We used the same serial interval
parameters for all variant categories due to the lack of consensus regarding differences.41,42 We reported the resulting mean Rt
estimates across the 1,000 samples and the 95% confidence intervals, calculated as the 2.5 and 97.5% quantiles across the
1,000 mean Rt estimates (Figure 3A). We plotted the daily mean Rt ratio and 95% confidence intervals for Delta versus Alpha over
time (Figure 3B). The mean Alpha/Delta co-circulation period across bootstrapped samples was 94 days for Connecticut, 76 for
Maine, 121 for Massachusetts, 97 for New Hampshire, 87 for Rhode Island, and 70 for Vermont. We plotted the mean estimated
Alpha and Delta infections per 100K during this time period in Figure S2A.
Multiplicative reproductive number estimates
Separately for Alpha and Delta, we calculated the multiplicative increase in Rt, a measure of relative transmissibility by multiplying the
coefficients from the previously described binomial logistic regression by the mean generation interval, 5.2 days, and exponentiating
to get an estimate of the increase in the probability of a given sequence belonging to a lineage over a generation interval.14 We plotted
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this against the log-transformed p value associated with each coefficient (Figure S3) to provide the level of support for the
multiplicative value estimate.
RT-qPCR CT value and virus RNA comparisons
We binned the RT-qPCR CT and virus RNA data (separately) for Alpha (January-March 2021) and Delta (June-August 2021) samples
and compared the group means for each institute using a t-test, with statistical significance symbols corresponding to the following
values: ns (p > 0.05), * (p % 0.05), ** (p % 0.01), *** (p % 0.001), **** (p % 0.0001) (Figures 4, S4C, and S4D). For the monthly analysis,
we ran a one-way ANOVA test for Alpha and Delta samples (separately) to test for significant differences between monthly mean CT
values (Figures S4A and S4B). For the Alpha samples, which returned a significant result, we ran post hoc Tukey’s HSD test to
investigate pairwise differences in monthly CT errors while controlling for the experiment-wise error rate. To calculate the ratio of
mean Alpha to mean Delta virus RNA copies per mL during their respective emergence periods, we sampled with replacement
(with size equal to each variant’s sample size), took the mean for Alpha and Delta separately, and calculated the ratio. We repeated
this 1,000 times and took the mean, 2.5%, and 97.5% quantiles across the samples. We reported the resulting mean and 95%
confidence intervals.
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